Zimmer Biomet Holdings (ZBH) Q4 2022 Earnings Call Transcript

Zimmer Biomet Holdings Inc. (NYSE:ZBH) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ET

Company Participants

Bryan Hanson - President, Chief Executive Officer

Suketu Upadhyay - Executive Vice President, Chief Financial Officer

Ivan Tornos - Chief Operating Officer

Keri Mattox - Senior Vice President, Chief Communications and Administration Officer

Conference Call Participants

Ryan Zimmerman - BTIG

Mike Matson - Needham & Co.

Larry Biegelsen - Wells Fargo

Travis Steed - Bank of America

Drew Ranieri - Morgan Stanley

Josh Jennings - Cowen

Robbie Marcus - JP Morgan

Jayson Bedford - Raymond James

Kyle Rose - Canaccord Genuity

Chris Pasquale - Nephron

Rick Wise - Stifel

Operator

Good morning ladies and gentlemen and welcome to the Zimmer Biomet fourth quarter 2022 earnings conference call. If anyone needs assistance at any time during the conference, please press the star followed by the zero. As a reminder, this conference is being recorded today, February 3, 2023.

Following today’s presentation, there will be a question and answer session. At this time, all participants are in a listen-only mode. If you have a question, please press the star followed by the one on your pushbutton phone.

I would now like to turn the conference over to Keri Mattox, Senior Vice President, Chief Communications and Administration Officer. Please go ahead.

Keri Mattox

Thank you Operator and good morning everyone. I hope you are all well and safe. Welcome to Zimmer Biomet’s fourth quarter 2022 conference call. Joining me today are Bryan Hanson, our Chairman, President and CEO; EVP and CFO, Suke Upadhyay, and COO Ivan Tornos.

Before we get started, I’d like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please note we assume no obligation to update these forward-looking statements even if actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties in addition to the inherent limitations of such forward-looking statements.

Additionally, the discussions on this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included within our Q4 earnings release, which can be found on our website, zimmerbiomet.com.

With that, I’ll turn the call over to Bryan. Bryan?